Wanjia Group Raises HK$40.8 Million Through Fully Placed Rights Issue

Wanjia Group Holdings Ltd. ( (HK:0401) ) has issued an update.

Wanjia Group Holdings completed a rights issue of one new share for every existing share, which was initially under-subscribed, with valid applications covering about 54% of the offered shares. The remaining 45.98% of unsubscribed rights shares, totaling 257,604,807 shares, were successfully placed with at least six independent investors at HK$0.08 per share, resulting in no net gain distributable to shareholders who took no action.

With all conditions fulfilled, the rights issue became unconditional on 26 March 2026 and generated gross proceeds of approximately HK$44.82 million and net proceeds of about HK$40.82 million. The company plans to use roughly 42.4% of the net funds to support and expand its pharmaceutical and hemodialysis businesses and related healthcare investments, about 33.1% to reduce trade and other payables and repay a director’s loan, and the remaining 24.5% for general working capital, strengthening its balance sheet and operational flexibility.

The most recent analyst rating on (HK:0401) stock is a Hold with a HK$0.11 price target. To see the full list of analyst forecasts on Wanjia Group Holdings Ltd. stock, see the HK:0401 Stock Forecast page.

More about Wanjia Group Holdings Ltd.

Wanjia Group Holdings Ltd. is a Cayman Islands-incorporated company listed in Hong Kong that operates a pharmaceutical wholesale and distribution business, alongside hemodialysis treatment and consultancy services. The group is focused on the medical and healthcare sectors and allocates capital to strengthen its existing operations while exploring related investment opportunities.

Average Trading Volume: 647,499

Technical Sentiment Signal: Buy

Current Market Cap: HK$143.4M

For a thorough assessment of 0401 stock, go to TipRanks’ Stock Analysis page.